Signal Transduction and Targeted Therapy (Sep 2023)

Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines

  • Ye Peng,
  • Lin Zhang,
  • Chris K. P. Mok,
  • Jessica Y. L. Ching,
  • Shilin Zhao,
  • Matthew K. L. Wong,
  • Jie Zhu,
  • Chunke Chen,
  • Shilan Wang,
  • Shuai Yan,
  • Biyan Qin,
  • Yingzhi Liu,
  • Xi Zhang,
  • Chun Pun Cheung,
  • Pui Kuan Cheong,
  • Ka Long Ip,
  • Adrian C. H. Fung,
  • Kenneth K. Y. Wong,
  • David S. C. Hui,
  • Francis K. L. Chan,
  • Siew C. Ng,
  • Hein M. Tun

DOI
https://doi.org/10.1038/s41392-023-01629-8
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 11

Abstract

Read online

Abstract The role of gut microbiota in modulating the durability of COVID-19 vaccine immunity is yet to be characterised. In this cohort study, we collected blood and stool samples of 121 BNT162b2 and 40 CoronaVac vaccinees at baseline, 1 month, and 6 months post vaccination (p.v.). Neutralisation antibody, plasma cytokine and chemokines were measured and associated with the gut microbiota and metabolome composition. A significantly higher level of neutralising antibody (at 6 months p.v.) was found in BNT162b2 vaccinees who had higher relative abundances of Bifidobacterium adolescentis, Bifidobacterium bifidum, and Roseburia faecis as well as higher concentrations of nicotinic acid (Vitamin B) and γ-Aminobutyric acid (P < 0.05) at baseline. CoronaVac vaccinees with high neutralising antibodies at 6 months p.v. had an increased relative abundance of Phocaeicola dorei, a lower relative abundance of Faecalibacterium prausnitzii, and a higher concentration of L-tryptophan (P < 0.05) at baseline. A higher antibody level at 6 months p.v. was also associated with a higher relative abundance of Dorea formicigenerans at 1 month p.v. among CoronaVac vaccinees (Rho = 0.62, p = 0.001, FDR = 0.123). Of the species altered following vaccination, 79.4% and 42.0% in the CoronaVac and BNT162b2 groups, respectively, recovered at 6 months. Specific to CoronaVac vaccinees, both bacteriome and virome diversity depleted following vaccination and did not recover to baseline at 6 months p.v. (FDR < 0.1). In conclusion, this study identified potential microbiota-based adjuvants that may extend the durability of immune responses to SARS-CoV-2 vaccines.